Advertisement
Advertisement
U.S. markets open in 2 hours 14 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Orgenesis Inc. (ORGS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.2100+0.1500 (+7.28%)
At close: 01:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.0600
Open2.1613
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range2.0400 - 2.2100
52 Week Range1.1300 - 4.0400
Volume11,652
Avg. Volume106,984
Market Cap56.456M
Beta (5Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ORGS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Orgenesis Inc.
    Daily – Vickers Top Buyers & Sellers for 11/09/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    19 days agoArgus Research
View more
  • GlobeNewswire

    Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022

    Secures up to $50 Million of Funding from Metalmark Capital Partners Expected to Accelerate Rollout of Point-of-Care Services Reduces operating expenses by 49% to achieve nearly breakeven income from operation for the third quarter of 2022 Orgenesis to Host Conference Call on Friday, November 11, 2022 at 8:00 AM Eastern Time GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potentia

  • GlobeNewswire

    Orgenesis Schedules Third Quarter 2022 Business Update Conference Call

    GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, November 11, 2022 to discuss the company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 fo

  • GlobeNewswire

    Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services

    GERMANTOWN, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and Metalmark Capital Partners (“Metalmark”), a leading private equity firm with extensive expertise in the healthcare sector, today announced an investment partnership whereby Metalmark has agreed to make a growth investment of up to $50 million in Orgenesis’ US-based

Advertisement
Advertisement